Molecular epidemiology of HIV-1 strains in the south-east and east of Turkey  by Çelen, Mustafa Kemal et al.
HOSTED BY Contents lists available at ScienceDirect
Asian Pac J Trop Biomed 2015; 5(9): 773–777 773Asian Paciﬁc Journal of Tropical Biomedicine
journal homepage: www.elsevier.com/locate/apjtbEpidemiological investigation http://dx.doi.org/10.1016/j.apjtb.2015.07.009*Corresponding author: Dr. Tuba Dal, Medical Faculty, Yildirim Beyazit Uni-
versity, Ankara, Turkey.
Tel: +90 312 324 1555
E-mail: tuba_dal@yahoo.com
Peer review under responsibility of Hainan Medical University.
Foundation Project: Supported by Dicle University Medical Faculty (Grant No.
13-TF-91).
2221-1691/Copyright © 2015 Hainan Medical University. Production and hosting by Elsevier (Singapore) Pte Ltd. This is an open acces
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Molecular epidemiology of HIV-1 strains in the south-east and east of TurkeyMustafa Kemal Çelen1, Murat Sayan2,3, Tuba Dal4*, Celal Ayaz1, Alicem Tekin1, Tuncer O¨zekinci1,
5 6 1 7 1Suda Tekin Koruk , Tunga Barcin , Recep Tekin , Mehmet Sinan Dal , Sevgi Kalkanlı
1Dicle University, Diyarbakır, Turkey
2Clinical Laboratory, Kocaeli University, Kocaeli, Turkey
3Research Center of Experimental Health Sciences, Near East University, Nicosia, North Cyprus, Turkey
4Yildirim Beyazit University, Ankara, Turkey
5Harran University, Urfa, Turkey
6Kiziltepe State Hospital, Mardin, Turkey
7Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TurkeyARTICLE INFO
Article history:
Received 11 May 2015
Received in revised form 21 May
2015
Accepted 27 Jun 2015
Available online 4 Aug 2015
Keywords:
HIV-1
Turkey
Molecular epidemiology
Refugee movementABSTRACT
Objective: To detect the subtype characterization and drug-resistant mutations in HIV-1 strains
after the refugee movement from Syria to Turkey between 2011 and 2014 in south east border lines.
Methods: A total of 65 patients were included in this study, of which 57 (88%) patients were
antiretroviral therapy-naive patients. HIV-1 RNA was detected and quantiﬁed by real-time PCR
assay. HIV-1 subtypes and circulating recombinant forms (CRFs) were identiﬁed by phylogenetic
analysis (neighbor-joining method), and drug-resistant mutations were analyzed.
Results: Three major HIV groups were indicated. Two of these groups were located in subtype B.
The other group showed heterogeneity. Subtype B (48/65, 73.8%), followed by CRFs (12/65, 18.5%)
was the most common strain. Subtype of CRFs consisted of CRF01_AE (9/65, 13.8%) and
CRF02_AG (3/65, 4.6%). Subtype C (1/65, 1.5%), sub-subtypes A1 (2/65, 3.1%) and F1 (2/65,
3.1%) were also detected with low prevalence. The rate of overall primary antiretroviral resistance
was 4.9% (3/61). Drug-resistant rate for non-nucleoside reverse transcriptase inhibitors was 4.9%.
The thymidine analogue mutation rate was 13.1% (8/61).
Conclusions: HIVmolecular epidemiology studies are necessary to determine transmission patterns
and spread. Subtype B and CRF01_AE, CRF02_AG are the most prevalent strains in the south-east of
Turkey. However, subtype C, sub-subtypes A1 and F1 are of low prevalence but persist in the south-east
of Turkey. In the near future, changing of HIV epidemiologywill be possible in Turkey due tomigration
movement in border lines and resistance testing will play an important role in HIV management.1. Introduction
HIV is a signiﬁcant public health problem. HIV has two major
genotypes including HIV-1 and HIV-2. HIV-1, the most prevalent
genotype worldwide, is characterised by a high genetic variability and
divided into three groups. Group M is responsible for the HIV
pandemic. Group M has several subtypes including A, B, C, D, F, G,
H, J, and a number of mosaic strains known as circulating recombi-
nant forms (CRFs) [1–3]. Subtype A is the predominant variant in the
Central and Eastern Africa; subtype B is common in the Western and
Central Europe, in America, Australia, and Southeastern Asia;subtype C is in Southern Africa and India [4,5]. In addition,
CRF01_AE is the most common CRF in Southeastern Asia while
CRF02_AG is frequent in Western and Central Africa [4–7]. World
Health Organization (WHO) reported that since the beginning of
the epidemic, almost 78 million people have been infected with
HIV and about 39 million people have died of HIV at the end of
2013, worldwide. According to this report, about 0.8% of adults are
living with HIV. Especially Sub-Saharan Africa remains the most
severely affected, with nearly 1 in every 20 adults living with HIV [7].
HIV-1 incidence has decreased by estimated 33% since 2001 but
remains high with approximately 2.3 million new infections in 2012.
In the United States, approximately 50000 new HIV infections were
encountered each year [8].
Zidovudine became the ﬁrst approved drug for treatment of HIV
disease in 1897. Since then, approximately 30 drugs have been
approved for HIV therapy. The treatment of HIV/AIDS normally
includes the combination therapy of multiple antiretrovirals. There
are several classes of antiretroviral agents that function on differents article under the CC BY-NC-ND
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transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), protease inhibitors, entry/fusion inhibitors, C–
C-chemokine receptor type 5 antagonists, and integrase inhibitors [9].
A combination therapy of drugs that act on different viral targets is
known as highly active antiretroviral therapy (ART) [10]. Recently,
because of antiretroviral resistance, antiretroviral failure may occur
in patients with HIV [8,11]. Viral mutations are the major cause of
therapy failure in patients with HIV. South-east and east regions of
Turkey are big areas with high population. In addition, in recent years,
there are frequent movements of refugees in borders of south-east and
east of Turkey. There were insufﬁcient data available regarding the
subtype distribution and antiretroviral resistance mutations in HIV-1
strains in these regions of Turkey. Therefore, we aimed to detect the
subtype distribution in 65 HIV-1 patients from south-east and east
regions of Turkey and to determine the primary antiretroviral drug-
resistant mutations in ART-naive HIV-1 patients.
2. Materials and methods
2.1. Patients
This study was performed between June 2009 and February
2012. A total of 65 HIV-1 patients were included in this study. Sera
of 65 HIV-positive patients were collected from provinces including
Diyarbakır, Gaziantep, S¸anlıurfa, Mardin, Batman, Siirt, Bitlis, and
Elazıg located in south-east and east of Turkey.
Of the patients, 57 (88%) were newly diagnosed and ART-naive
HIV-1 patients, while 8 were under different ARTs. All patients
were categorized as HIV-1 carriers according to European AIDS
Clinical Society Guidelines [10].
The U.S. Centers for Disease Control and Prevention classiﬁ-
cation system was used to stage HIV infections [12]. Blood samples
were immediately separated by centrifugation, aliquoted, and then
stored at −80 C. Anti-HIV 1/2 antibody titers were detected by
commercially available microparticle enzyme immunoassay kits
(Axsym, Abbott Laboratories, Abbott Park, III., USA and Elecsys,
Roche Diagnostics GmbH, Mannheim, Germany). In the study, all
anti HIV antibody reactive samples were conﬁrmed by ELISA, at
least for twice, and were further conﬁrmed by Western blot analysis
(DIA PRO, HIV-1 LIA, Diagnostic Bioprobes Srl, Milano, Italy).
Ethic approval was obtained from Ethics Committee, Faculty of
Medicine, Dicle University, Diyarbakir, Turkey.
2.2. HIV-1 RNA isolation and real-time PCR
HIV-1 RNA was detected and quantiﬁed from serum samples by
using commercial real-time PCR assays (COBAS, Ampliprep/
COBAS, and TaqMan HIV-1 Test, Roche Molecular Systems, Inc.
Pleasanton, Calif., USA and Abbott M2000 SP/Abbott RealTimeTable 1
Primers used for ampliﬁcation and sequencing of reverse transcriptase and p
Genes
Forward
Reverse transcriptase
Outer MJ3:50-AGTAGGACCTACACCTGTCA-30 (2480-2499)
Inner A(35):50-TTGGTTGCACTTTAAATTTTCCCATTAGTCCTATT-3
Sequences A(20):50- ATTTTCCCATTAGTCCTATT-30
Protease
Outer 50prot1:50-TAATTTTTTAGGGAAGATCTGGCCTTCC-30 (2082-2
Inner 50prot2:50-TCAGAGCAGACCAGAGCCAACAGCCCCA-30 (2136
Sequences 30prot2:50-AATGCTTTTATTTTTTCTTCTGTCAATGGC-30 (2621HIV-1 ampliﬁcation kit, Abbott Molecular Inc., Des Plaines, III.,
USA).
2.3. Population-based sequencing of HIV-1 pol
Primer pairs were designed based on the French National
Agency for AIDS Research AC11 Resistance Group (www.
hivfrenchresistance.org) for analysis of pol sequences (reverse
transcriptase and protease regions) of HIV-1. The sequence and
location of each primer are given in Table 1.
First strand cDNA synthesis kit (Thermo Scientiﬁc Inc., Fer-
mentas, Lithuania) including the Moloney murine leukemia virus
reverse transcriptase enzyme was used for HIV-1 cDNA synthesis.
Then PCR ampliﬁcation was carried out in the following conditions:
at 95 C for 10min, then 45 cycles at 95 C for 45 s, 55 C for 45 s, and
72 C for 45 s. PCR products was puriﬁed by the highly pure PCR
product puriﬁcation kit (Roche Diagnostics) and directly sequenced
by using theABI PRISM310 genetic analyzerwith theDYEnamic ET
terminator cycle sequencing kit (Amersham Pharmacia Biotech Inc.,
Piscataway, N.J., USA). Thermal protocol for the cycle sequencing
was as follows: 35 cycles at 95 C for 20 s, 50 C for 25 s, and 60 C
for 2 min. The sequences obtained from the electropherogram were
assembled by using Vector NTI 5.1 software (InforMax, Invitrogen,
Life Science Software, Frederick, Md., USA).
2.4. HIV-1 subtyping
Neighbor-joining method was carried out with other sequences
from all HIV-1 subtypes from GenBank by using CLC sequence
viewer 7.5 software (Qiagen, CLC bio A/S, Aarhus, Denmark).
Bootstrap support values (1000 replicates) were shown at the
respective branches. The consensus reference sequences of HIV-1
subtypes were obtained from Los Alamos National Laboratory
(www.hiv.lanl.gov) database.
2.5. Determination of antiretroviral drug-resistant
mutations
HIV-1 antiretroviral drug-resistant mutations were performed in a
total of 61 patients and analyzed according to criteria established by
the WHO (last updated in 2009) for surveillance of drug-resistant
mutations. WHO criteria for surveillance of drug-resistant muta-
tions included only nonpolymorphic drug-resistant mutations, which
were deﬁned as those occurring at a prevalence0.5% in ART-naive
individuals in subtypes for which >1000 sequences were available
[13]. Antiretroviral drug-resistant mutations were also interpreted by
using the Stanford University HIVdb algorithm (www.hivdb.
stanford.edu). The information was then compared to the consensus
subtype B reference sequence, and the differences were used as query
parameters to interrogate the HIV drug resistance database [14].rotease genes.
Primes
Reverse
MJ4,50-CTGTTAGTGCTTTGGTTCCTCT-30 (3399-3420)
0 (2530-2558) NE1(35):50-CCTACTAACTTCTGTATGTCATTGACAGT
CCAGCT-30 (3300-3334)
109) 30prot1:50-GCAAATACTGGAGTATTGTATGGATTTT
CAGG-30 (2703-2734)
-2163)
-2650)
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Differences between two proportions were measured by using
Pearson's Chi-squared test or Fisher's exact test. P < 0.05 was
considered as statistically signiﬁcant. Statistical analyses were per-
formed by using SPSS 13.0.0 Windows statistical software (SPSS
Inc., Chicago, III., USA).Figure 1. Phylogenetic tree of HIV-1 reverse transcriptase (codon 41-238) an3. Results
Among 65 patients, 57 (88%) were newly diagnosed and ART-
naive patients, while 8 were under different ARTs. The population-
based sequencing of the reverse transcriptase and protease domains
of pol gene region of HIV-1 indicated that subtype B (48/65,
73.8%), followed by CRFs (12/65, 18.5%) was the most commonlyd protease (codon 1-99) domains (~667 bp) of pol gene region.
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13.8%) and CRF02_AG (3/65, 4.6%). Subtype C (1/65, 1.5%), sub-
subtypes A1 (2/65, 3.1%) and F1 (2/65, 3.1%) were also detected
with low prevalence (Figure 1).
Three major groups were obtained in phylogenetic analysis. Two
of these groups were located in subtype B. The other group showed
heterogeneity and consisted of CRF02_AG, CRF01_AE, subtype C,
CRF12_BF, and subtype A1 (Figure 1). The patients had antire-
troviral resistance mutations to NRTIs (M184V) and NNRTIs
(K103N, Y181C, K101E, K103S).
Among 61 patients, the prevalence of overall primary antiretro-
viral resistance was 4.9% (3/61). All of the patients with antiretro-
viral resistance have history of treatment with antiretroviral drugs.
Resistant rate for NRTIs and NNRTIs were 0% (0/61) and 4.9% (3/
61), respectively.
The rate of thymidine analogue mutations (M41L, D67N, K70R,
T215l, K219E, K70L, T215N, T215D, A62V, T215N, T215D,
V75L, K219Q) was 13% (8/61) in HIV-1 patients.
4. Discussion
Turkey is not an endemic country for HIV infection but ac-
cording to the HIV/AIDS surveillance data of the Turkey Ministry
of Health, 6802 patients were suffered from HIV-1 infection from
1985 through 2013 in Turkey [15]. First-line therapy choice is very
important for the management of HIV and it is related to drug
resistance caused by HIV mutations and subtypes. In recent years,
there are frequent movements of refugees in borders of south-east
and east of Turkey. There were insufﬁcient data available
regarding subtype distribution and antiretroviral resistant mutations
in HIV-1 strains in these regions.
In Turkey, the ﬁrst study on HIV-1 subtype was reported in
2006. A total of 27 HIV/AIDS patients were examined. HIV-1
subtype B was determined as the most prevalent subtype in
Turkey and the distribution of the non-B-subtypes was as follows:
four were subtype A, one subtype C, one subtype D, and two sub-
type F1. Non-B-subtype infections were thought to be mainly
transmitted by immigrants from Africa, the Balkans, and the Middle
East [16]. After this study, Hemelear described CRFs of HIV-1 in
Turkey for the ﬁrst time and also found that CRF02_AG was
prevalent in West and Central Africans, and Middle Easterns/North
Africans, CRF01_AE in South-East Asians, East Asians and Central
Africans, CRF03_AB in Eastern Europeans and Central Asians, and
CRF12_BF in South Americans [17].
A total of 72 HIV-1 patients inhabiting in Istanbul, Turkey were
included in a study between 2009 and 2012. Among those patients,
57 were newly diagnosed and ART-naive patients, while 15 were
under different ARTs. The population-based sequencing of the
reverse transcriptase region of HIV-1 indicated that CRFs (36/72;
50%) were the most commonly identiﬁed strains, followed by
subtype B (31/72; 43%) among Turkish patients. Subtypes A1
(4.2%) and F1 (2.8%) were also detected with low prevalence. In
that study, the recombinant forms of HIV-1 circulated in Istanbul,
Turkey were found as follows: CRF02_AG (25%, West Africa,
Central Africa and Middle East/North Africa origin), CRF12_BF
(12.5%, South America origin), CRF03_AB (9.7%, Eastern Europe
and Central Asia origin) and CRF01_AE (2.8%, South-East Asia,
East Asia and Central Africa origin) [18].
For the ﬁrst time, in 2013, a extreme subtype, CRF06_cpx was
reported in a HIV-1 positive married couple from Izmir, Turkey [19].
In the same year, subtype B (48%) was found to be the most
common subtype in 77 HIV-1 positive patients from Antalya,
Turkey, and CRF14_BG (12.9%) was identiﬁed for the ﬁrst time in
Antalya in contrast to previous observations in the other reports inTurkey [20]. In a different study, in 117 newly diagnosed HIV-1
positive patients, subtype CRFs (CRF02_AG, CRF01_AE,
CRF12_BF and CRF03_AB; 47.0%, 55/117) and subtype B
(33.3%, 39/117) were identiﬁed as the most common HIV-1 sub-
types [21]. Our study indicated that subtype B (73.8%), followed by
CRFs (18.5%) were the most prevalent strains. We found that
subtype of CRFs consisted of CRF01_AE and CRF02_AG. We
found that subtype C, subtypes A1 and F1 were of low prevalence
but persisted in south-east of Turkey. Turkey has a migration
movement in border lines of south-east and the Ministry of the
Interior, Turkey estimated that around one million people between
April 2011 and May 2014 migrated to Turkey due to internal turmoil
in Syria [22]. We suggested that in the near future, changing of HIV
epidemiology was possible in Turkey.
In the study of Sayan et al., the prevalence of overall primary
antiretroviral resistance was 7.6% in HIV-1 patients from Turkey
and drug-resistant rates for NRTIs, NNRTIs, and protease inhibitors
were 4.2%, 1.7%, and 1.7%, respectively [21]. A recent study
performed in 774 antiretroviral naive HIV-1 patients from Turkey
between 2009 and 2014 reported that the prevalence of overall
transmitted drug resistance mutations was 6.7% (52/774). Resis-
tance mutations were found to be 0.7%, 4.1% and 2.1% to NRTIs,
NNRTIs and protease inhibitors, respectively. Three patients had
NRTIs + NNRTs resistance mutations (M184V + K103N) as multi-
class drug resistance. However, thymidine analogue resistance mu-
tations (TAMs) determined two distinct genotypic proﬁles in the
HIV-1 reverse transcriptase: TAM1 (M41L, L210W and T215Y),
and TAM2 (D67N, K70R, K219E/Q, and T215F). The prevalence
of TAM1 and TAM2 was 7.8% (60/774) and 4.4% (34/774),
respectively [23]. In our study, the prevalence of overall primary
antiretroviral resistance was 4.9% (3/61) (treatment naive) in HIV-
1 patients and drug-resistant rate for NRTIs and NNRTIs were 0%
and 4.9%, respectively. The TAMs (M41L, D67N, K70R, T215l,
K219E, K70L, T215N, T215D, A62V, T215N, T215D, V75L,
K219Q) was 13% in HIV-1 patients. Our study suggested that the
prevalence of HIV-1 primary drug-resistant mutations was in sub-
stantial rates and resistance testing should be incorporated as an
integral part of HIV management, and the choice of a ﬁrst-line
therapy regime in our patients.
In conclusion, subtype B and CRF01_AE, CRF02_AG were the
most prevalent strains in south-east of Turkey. Subtype C, subtypes
A1 and F1 were of low prevalence but persisted in south-east of
Turkey. The movements of refugees in the border lines of Turkey
may change the circulating HIV-1 strain pool and the molecular
epidemiology researchs on HIV-1 may be more important than ever.
It should be mentioned that development of the effective vaccine for
HIV is an important public health concern and global monitoring of
HIV subtypes will supply data for HIV vaccine development
studies. Our study revealed that the resistance testing should be an
integral part of the HIV infection management.
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